KOD Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 7.47%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -18.75%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 9.17%. Given that Arcutis Biotherapeutics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Arcutis Biotherapeutics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 11.64x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -15814.98%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Cytokinetics, Inc.'s return on equity of --.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -18.75%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $85.44 which suggests that it could grow by 35.39%. Given that Cytokinetics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Cytokinetics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Cytokinetics, Inc. quarterly revenues of $1.9M. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 86.12x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -82.06%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -18.75%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 10.08%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 13.61x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Processa Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of --. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Processa Pharmaceuticals, Inc.'s return on equity of -309.65%.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -18.75%. On the other hand Processa Pharmaceuticals, Inc. has an analysts' consensus of $1.00 which suggests that it could grow by 537.76%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Processa Pharmaceuticals, Inc. has a beta of 1.094, suggesting its more volatile than the S&P 500 by 9.404%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Processa Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Processa Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Processa Pharmaceuticals, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Processa Pharmaceuticals, Inc.'s net income of -$3.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Processa Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus -- for Processa Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.